BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin’s Pipeline
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to…